SenzaGen
6,9
SEK
+1,47 %
SENZA
First North Stockholm
Medical Equipment & Services
Health Care
Mindre end 1K følgere
+1,47%
0%
-1,43%
-8%
-2,13%
-0,86%
-33,97%
-61,37%
-83,67%
Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.
Læs mereMarkedsværdi
203,58 mio. SEK
Aktieomsætning
6,9 t SEK
Omsætning
49,87 mio.
EBIT %
-45,1 %
P/E
-
Udbytteafkast, %
-
Finanskalender
13.2
2025
Årsrapport '24
ViserAlle indholdstyper
SenzaGen’s interim report January–September 2024: Strong quarter with over 30% growth
SenzaGen will present at the BioStock Life Science Summit, November 21
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools